Advertisement

Topics

3% AND 5% SODIUM CHLORIDE INJECTION, USP IN VIAFLEX PLASTIC CONTAINER | Sodium Chloride [Baxter Healthcare Corporation] | BioPortfolio

13:43 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

3% and 5% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. The pH may have been adjusted with hydrochloric acid. It contains no antimicrobial agents. Composition, ionic concentration, osmolarity, and pH are shown in Table 1.

The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.

Table 1.
size (mL) Composition
(g/L)
Ionic Concentration
(mEq/L)
Normal physiological osmolarity range is approximately 280 to 310 mOsmol/L.Osmolarity (mOsmol/L)
(calc)
pH
Sodium
Chloride
USP (NaCl)
Sodium Chloride
3% Sodium Chloride
Injection,
USP
500 30 513 513 1027 5.0
(4.5 to 7.0)
5% Sodium Chloride
Injection,
USP
500 50 856 856 1711 5.0
(4.5 to 7.0)

3% and 5% Sodium Chloride Injection, USP has value as a source of water and electrolytes. It is capable of inducing diuresis depending on the clinical condition of the patient.

3% and 5% Sodium Chloride Injection, USP is indicated as a source of water and electrolytes.

None known.

Hypersensitivity/infusion reactions, including hypotension, pyrexia, tremor, chills, urticaria, rash, and pruritus may occur with 3% and 5% Sodium Chloride Injection, USP.

Stop the infusion immediately if signs or symptoms of a hypersensitivity reaction develop, such as tachycardia, chest pain, dyspnea and flushing. Appropriate therapeutic countermeasures must be instituted as clinically indicated.

Depending on the volume and rate of infusion, the intravenous administration of 3% and 5% Sodium Chloride Injection, USP can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration/hypervolemia, congested states, pulmonary edema, or acid-base imbalance. The risk of dilutive states is inversely proportional to the electrolyte concentration of the injection. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injection.

Monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.

Administer 3% and 5% Sodium Chloride Injection, USP with particular caution to patients with or at risk for hypernatremia, hyperchloremia, hypervolemia or with conditions that may cause sodium retention, fluid overload and edema; such as patients with primary hyperaldosteronism, or secondary hyperaldosteronism (for example, associated with hypertension, congestive heart failure, liver disease (including cirrhosis), renal disease (including renal artery stenosis, nephrosclerosis) or pre-eclampsia). Certain medications may increase risk of sodium and fluid retention, see DRUG INTERACTIONS.

Administer 3% and 5% Sodium Chloride Injection, USP with particular caution to patients with severe renal impairment. In such patients administration of Sodium Chloride Injection, USP may result in sodium retention.

Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.

Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.

Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.

3% and 5% Sodium Chloride Injection, USP is hypertonic with an osmolarity of 1027 mOsmol/L and 1711 mOsmol/L, respectively. Administration of hypertonic solutions may cause venous damage and thus should be administered through a large vein, for rapid dilution.

Do not mix or administer 3% and 5% Sodium Chloride Injection, USP solutions through the same administration set with whole blood or cellular blood components.

Rapid correction of hypo- and hypernatremia is potentially dangerous (risk of serious neurologic complications). Dosage, rate, and duration of administration should be determined by a physician experienced in intravenous fluid therapy.

Caution must be exercised in the administration of 3% and 5% Sodium Chloride Injection, USP to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids.

Caution is advised in patients treated with lithium. Renal sodium and lithium clearance may be increased during the administration of 3% and 5% Sodium Chloride Injection, USP. Administration of 3% and 5% Sodium Chloride Injection, USP may, therefore, result in decreased lithium levels.

There are no adequate and well controlled studies with 3% and 5% Sodium Chloride Injection, USP in pregnant women and animal reproduction studies have not been conducted with this drug. Therefore, it is not known whether 3% and 5% Sodium Chloride Injection, USP can cause fetal harm when administered to a pregnant woman. 3% and 5% Sodium Chloride Injection, USP should be given during pregnancy only if the potential benefit justifies the potential risks to the fetus.

It is not known whether this drug is excreted present in human milk. Because many drugs are excreted present in human milk, caution should be exercised when 3% and 5% Sodium Chloride Injection, USP is administered to a nursing woman.

The use of 3% and 5% Sodium Chloride Injection, USP in pediatric patients is based on clinical practice. (See DOSAGE AND ADMINISTRATION)

Plasma electrolyte concentrations should be closely monitored in the pediatric population as this population may have impaired ability to regulate fluids and electrolytes.

Clinical studies of 3% and 5% Sodium Chloride Injection, USP, did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

The following adverse reactions have not been reported with 3% and 5% Sodium Chloride Injection, USP but may occur:

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

Excessive administration of 3% and 5% Sodium Chloride Injection, USP may lead to hypernatremia (which can lead to CNS manifestations, including seizures, coma, cerebral edema and death) and sodium overload (which can lead to central and/or peripheral edema).

When assessing an overdose, any additives in the solution must also be considered. The effects of an overdose may require immediate medical attention and treatment.

As directed by a physician. Dosage, rate, and duration of administration are to be individualized and depend upon the indication for use, the patient’s age, weight, clinical condition, concomitant treatment, and on the patient’s clinical and laboratory response to treatment.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions, where possible.

Do not administer unless solution is clear and seal is intact.

All injections in VIAFLEX plastic containers are intended for intravenous administration using sterile and nonpyrogenic equipment.

Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.

After opening the container, the contents should be used immediately and should not be stored for a subsequent infusion. Do not reconnect any partially used containers. Discard any unused portion.

3% and 5% Sodium Chloride Injection, USP in VIAFLEX plastic container is available as follows:

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C/77°F); brief exposure up to 40°C /104°F does not adversely affect the product.

Code Size (mL) NDC Product Name
2B1353 500 0338-0054-03 3% Sodium Chloride
Injection, USP
2B1373 500 0338-0056-03 5% Sodium Chloride
Injection, USP

For Information on Risk of Air Embolism – see PRECAUTIONS.

Tear overwrap down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below.

Warning: Additives may be incompatible - see DOSAGE AND ADMINISTRATION.

Baxter Healthcare Corporation Deerfield, IL 60015 USA Printed in USA

07-19-00-0269

Rev. May 2018

Baxter and Viaflex are trademarks of Baxter International Inc.

LOT

EXP

2B1353

NDC 0338-0054-03

Hypertonic Saline

3% Sodium Chloride Injection USP

500mL

EACH 100 mL CONTAINS 3 g SODIUM CHLORIDE USPpH MAY HAVE BEEN ADJUSTED WITH HYDROCHLORIC ACIDpH 5.0 (4.5 TO 7.0) mEq/L SODIUM 513 CHLORIDE 513OSMOLARITY 1027 mOsmol/L (CALC) HYPERTONIC MAY CAUSEVEIN DAMAGE STERILE NONPYROGENIC SINGLE DOSE CONTAINERADDITIVES MAY BE INCOMPATIBLE CONSULT WITH PHARMACIST IFAVAILABLE WHEN INTRODUCING ADDITIVES USE ASEPTIC TECHNIQUEMIX THOROUGHLY DO NOT STORE DOSAGE INTRAVENOUSLY ASDIRECTED BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZEAND INSPECT INNER BAG WHICH MAINTAINS PRODUCT STERILITYDISCARD IF LEAKS ARE FOUND MUST NOT BE USED IN SERIESCONNECTIONS DO NOT USE UNLESS SOLUTION IS CLEAR RX ONLYSTORE UNIT IN MOISTURE BARRIER OVERWRAP AT ROOMTEMPERATURE (25°C/77°F) UNTIL READY TO USE AVOIDEXCESSIVE HEAT SEE INSERT

VIAFLEX CONTAINER

PL 146 PLASTIC

BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OFBAXTER INTERNATIONAL INC

FOR PRODUCT INFORMATION 1-800-933-0303

Baxter Logo BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA

MADE IN USA

LOT

EXP

2B1373

NDC 0338-0056-03

Hypertonic Saline

5% Sodium Chloride Injection USP

500mL

EACH 100 mL CONTAINS 5 g SODIUM CHLORIDE USPpH MAY HAVE BEEN ADJUSTED WITH HYDROCHLORIC ACIDpH 5.0 (4.5 TO 7.0) mEq/L SODIUM 856 CHLORIDE 856OSMOLARITY 1711 mOsmol/L (CALC) HYPERTONIC MAY CAUSE VEIN DAMAGE STERILE NONPYROGENIC SINGLE DOSE CONTAINER ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH PHARMACIST IF AVAILABLE WHEN INTRODUCING ADDITIVES USE ASEPTIC TECHNIQUEMIX THOROUGHLY DO NOT STORE DOSAGE INTRAVENOUSLY AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT BE USED IN SERIES CONNECTIONS DO NOT USE UNLESS SOLUTION IS CLEAR RX ONLY STORE UNIT IN MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE (25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT SEE INSERT

VIAFLEX CONTAINER

PL 146 PLASTIC

BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OFBAXTER INTERNATIONAL INC

FOR PRODUCT INFORMATION 1-800-933-0303

Baxter Logo BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA

MADE IN USA

Manufacturer

Baxter Healthcare Corporation

Active Ingredients

Source

Drugs and Medications [174 Associated Drugs and Medications listed on BioPortfolio]

Potassium chloride [novel laboratories, inc.]

These highlights do not include all the information needed to use POTASSIUM CHLORIDE safely and effectively. See full prescribing information for POTASSIUM CHLORIDE POTASSIUM CHLORIDE for oral solutio...

Potassium chloride for oral solution [virtus pharmaceuticals]

These highlights do not include all the information needed to use POTASSIUM CHLORIDE safely and effectively. See full prescribing information for POTASSIUM CHLORIDE. POTASSIUM CHLORIDE for oral soluti...

Potassium chloride [par pharmaceutical]

These highlights do not include all the information needed to use POTASSIUM CHLORIDE safely and effectively. See full prescribing information for POTASSIUM CHLORIDE. POTASSIUM CHLORIDE for oral soluti...

Potassium chloride [epic pharma, llc]

These highlights do not include all the information needed to use POTASSIUM CHLORIDE safely and effectively. See full prescribing information for POTASSIUM CHLORIDE.POTASSIUM CHLORIDE for oral solutio...

Potassium chloride [golden state medical supply inc.]

POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES These highlights do not include all the information needed to use POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing...

Clinical Trials [1908 Associated Clinical Trials listed on BioPortfolio]

Fluid Therapy During Brain Tumor Resection in Children

Fluid management of children during neurosurgery is not well established. Hypotonic solutions, commonly still used in pediatric patients, may enhance cerebral edema and worse operative con...

Clinical Evaluation of the Use of Sealed Capsule Irrigation With Sodium Chloride During Pediatric Cataract Surgery and IOL Implantation

This study involves using both a device that seals the capsular bag (where the lens is located) allowing safer irrigation of the capsular bag and sodium chloride to irrigate the capsular b...

Prevention of Contrast Nephropathy by Sodium Bicarbonate Versus Sodium Chloride and N-acetylcysteine

The objective of this study is to assess the efficacy of sodium bicarbonate compared with sodium chloride and oral N-acetylcysteine (NAC ) pretreatment for prevention of contrast nephropat...

Safety and Efficacy Study of the Use of Sodium Pyruvate Bronchodilation in Asthmatics

Sodium pyruvate in sodium chloride solution will be delivered by nebulization to the lungs. It is believed that this administration will produce bronchodilation in asthmatics as determined...

Sodium Chloride and Contrast Nephropathy

This phase II, open, non-inferiority, randomized and controlled clinical trial is aimed to ascertain the incidence of contrast nephropathy in outpatients undergoing CT scan with contrast. ...

PubMed Articles [2288 Associated PubMed Articles listed on BioPortfolio]

The adequate amount of sodium chloride in Protein A wash buffer for effective host cell protein clearance.

Post-load column wash in Protein A chromatography can effectively improve host cell protein (HCP) clearance. A commonly used wash additive for this purpose is sodium chloride. However, the adequate am...

Autointoxication with 'suicide powder'.

We present two patients who were treated for an intentional overdose of sodium nitrite. When ingested sodium nitrite leads to severe methaemoglobinaemia, resulting in severe hypoxia (as methaemoglobin...

Urine chloride self-measurement to monitor sodium chloride intake in patients with chronic kidney disease.

Background Excessive sodium intake is a risk factor for hypertension, cardiovascular disease and the risk for kidney failure in chronic kidney disease (CKD) patients. Methods We tested the diagnostic ...

Sodium Chloride Aggravates Arthritis via Th17 Polarization.

Sodium chloride (NaCl) has been proposed as a driving factor in autoimmune diseases through the induction of pathogenic CD4 T helper cells that produce interleukin-17 (Th17 cells). This study investig...

Does protein oxidation affect proteolysis in low sodium Chinese traditional bacon processing?

This work investigated protein oxidation, proteolysis and their interrelationship during the manufacturing process of low-sodium Chinese traditional bacon. The bacons were prepared by four different s...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record